
|Videos|March 15, 2021
Dr. Tward discusses his experience with the Prolaris test for prostate cancer
Author(s)Urology Times staff
“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
Advertisement
“I think that getting a really personalized risk estimator can give you a better handle on how much you need to do to achieve the best outcome,” says Jonathan D. Tward, MD, PhD, in discussing the Prolaris test and how his use of the test has evolved over time. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5

















